Fella Health

Challenger

SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026.

Updated March 2026

Company Overview

About Fella Health

Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed.

Business Model & Competitive Advantage

Fella Health's men's obesity telemedicine model capitalizes on the GLP-1 medication revolution in obesity treatment while adding the behavioral support that clinical evidence shows improves long-term outcomes: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) achieve 15-22% body weight reduction in clinical trials — but the drugs are expensive ($1,000-$1,300/month list price), require physician oversight, and work best when combined with lifestyle modification that sustains the metabolic changes after medication titration. Fella's subscription model (typically $150-300/month, far below GLP-1 medication list price) achieves the medication access and behavioral support combination by sourcing compounded semaglutide through FDA-registered compounding pharmacies during the branded GLP-1 supply shortage, providing physician prescribing through synchronous and asynchronous telemedicine consultations, and delivering the health coaching that supports sustainable behavior change alongside the medication.

Competitive Landscape 2025–2026

In 2025, Fella Health competes in the men's health telemedicine, GLP-1 obesity treatment, and direct-to-consumer metabolic health market with Ro (men's health telehealth, $876M raised at $5B valuation), Calibrate (metabolic health program, $100M raised), and Hims & Hers (NYSE: HIMS, men's and women's telehealth, $526M revenue 2024) for men with obesity and metabolic health telemedicine program adoption. The $50M+ ARR with $130K in external funding represents one of the most capital-efficient telehealth companies in the GLP-1 obesity treatment market. The cashflow positive milestone (24 months) demonstrates the business model sustainability that VC-heavy telehealth competitors have not yet achieved. The 2025 strategy focuses on the expansion to Fella's 1 million patient milestone, building the metabolic health monitoring platform for longitudinal GLP-1 treatment outcomes tracking, and growing the Delilah women's health brand as a parallel market opportunity.

Revenue
$50M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

Fella Health is an established challenger with significant market presence and competitive offerings in Healthcare.

Frequently Asked Questions

Not So Random Others

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

Adni

Healthcare
HealthtechSaasGlobal

Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital

Quantinuum

Technology
B2bGlobalHardwareInfrastructureQuantum

Quantinuum is a Cambridge, UK and Broomfield, Colorado-based integrated quantum computing company — majority owned by Honeywell (NASDAQ: HON) with $625+ million in total funding including a $300 milli

H&M (Hennes & Mauritz)

retail
B2cRetailtechPublicGlobalEurope

H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores

Scaleway

AI Infrastructure
B2bPlatformCloud NativeInfrastructureGlobalDeveloper Tools

Scaleway is a French cloud computing provider and subsidiary of Iliad Group, the telecommunications and technology conglomerate founded by billionaire Xavier Niel. Originally launched as Online.net in

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Compare Fella Health with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Fella Health

Claim This Profile

Are you from Fella Health? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Fella Health Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Fella Health vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →